Kalaris Therapeutics (NASDAQ:KLRS) Rating Increased to Strong-Buy at Chardan Capital

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by Chardan Capital to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

KLRS has been the subject of several other reports. Citizens Jmp started coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Raymond James Financial initiated coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Trading Down 4.0%

Shares of Kalaris Therapeutics stock opened at $9.66 on Tuesday. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $12.90. The firm has a market capitalization of $180.64 million, a PE ratio of -2.56 and a beta of -0.04. The firm’s 50-day moving average price is $6.20 and its 200 day moving average price is $4.45.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new position in Kalaris Therapeutics during the third quarter worth about $58,000. Bridgeway Capital Management LLC purchased a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $130,000. XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Belpointe Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $231,000. Finally, Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $231,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.